March 31st, 2025: Plaintiffs Push Back on Ozempic Dismissal Motion, Accuse Drug Makers of Downplaying GI Risks Plaintiffs in the GLP-1 drug litigationincluding claims involving Ozempic, Wegovy, and Mounjarohave asked a federal judge to reject dismissal efforts by Novo Nordisk and Eli Lilly
Current Research on Semaglutide and Gastrointestinal Health The majority of semaglutide research has focused on weight loss and diabetes management, but secondary analyses from cardiovascular and metabolic trials reveal interesting findings about digestive health
Batch-level CoA information is available where applicable and focuses on purity testing, lot details, and synthesis date
Glucagon-Like Peptide-1 Receptor Agonists and Age-Related Macular Degeneration
Your injection amount is in milli liters
Treatment decisions often depend on: The best option is the one that aligns with a patients health profile and can be followed consistently over time